Phaarmasia Limited has responded to a BSE surveillance inquiry regarding significant movement in its stock price, clarifying that the price changes appear to be market-driven with no undisclosed material information affecting the security.

Regulatory Compliance Confirmation

In response to BSE's email dated April 13, 2026, Phaarmasia Limited confirmed its adherence to regulatory requirements. The company stated it has been regularly complying with SEBI (LODR) Regulations, 2015, including Regulation 30 provisions for disclosure of material events.

Price Movement Assessment

The pharmaceutical company addressed the BSE's inquiry about recent price movements by providing a comprehensive assessment of potential factors. Phaarmasia noted that the communication from BSE referred to the "recent past" without specifying the exact period under consideration.

Key points from the company's assessment include:

• All price-sensitive information has been duly disclosed to the exchange
• No pending announcements that could impact stock price
• Movement appears purely market-driven
• General market conditions identified as primary factor

Company's Position on Transparency

Phaarmasia Limited emphasized its commitment to maintaining transparency in all dealings with regulatory authorities. Company Secretary and Compliance Officer Urvashi Bhatia, who signed the clarification, reiterated the company's dedication to prompt disclosure of material events.

The company assured stakeholders that it will continue to inform the exchange of any material events or information as required under applicable regulations. This response demonstrates the company's proactive approach to addressing regulatory inquiries and maintaining investor confidence.

Regulatory Framework Adherence

The clarification highlights Phaarmasia's systematic approach to regulatory compliance. The company confirmed that all events, information, and disclosures that may have a bearing on operations and performance have been communicated to the exchange in a timely manner.

This response to BSE surveillance reflects the company's understanding of its obligations under securities regulations and its commitment to maintaining market integrity through transparent communication.

Phaarmasia Limited has officially notified the stock exchange about the relocation of its registered office within Hyderabad's local limits. The pharmaceutical company has moved its registered office from its previous location to a new address within the same industrial area, maintaining its operational base in Telangana.

Office Relocation Details

The company has shifted its registered office within the IDA Jeedimetla area of Hyderabad. This internal move keeps the company within the same city limits while potentially providing enhanced operational capabilities.

Regulatory Compliance

Phaarmasia Limited has fulfilled its disclosure obligations by informing BSE Limited about this corporate change. The notification was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which mandates listed companies to disclose material events and corporate actions.

Company Secretary and Compliance Officer Urvashi Bhatia, with membership number ACS 46877, signed the official communication to the exchange. The company's scrip code 523620 on BSE remains unchanged following this relocation.

Corporate Information

Phaarmasia Limited, incorporated in 1981 with CIN L24239TG1981PLC002915, continues its operations from the Hyderabad base. The company maintains its contact information and business operations while transitioning to the new registered office address within the same industrial development area.